Intestinal Research
Cure8 research brief
Why This Matters
Choosing which biologic to start for ulcerative colitis appears to affect how much time patients spend in corticosteroid-free remission over the first 24 months. That could influence quality of life and future treatment planning.
Who Should Pay Attention
Adult patients with UC considering a first biologic, clinicians who prescribe biologics, and researchers studying biologic sequencing and real-world effectiveness.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study compared two real-world first-line biologic selection strategies for adults with active ulcerative colitis: an effectiveness-based strategy (EBS) using infliximab or vedolizumab, and an acceptability-based strategy (ABS) using adalimumab or golimumab.
Over follow-up, patients starting with EBS spent a larger percentage of months in corticosteroid-free patient-reported clinical remission (PRO2-CFREM) within the first 24 months than those starting with ABS. The authors analyzed 130 patients and adjusted comparisons with propensity scores.
The main take-home reported by the abstract is that initial choice of biologic materially affected outcomes and later switching did not fully compensate for a less-effective first choice. Who this matters to: if you or a patient is starting a first biologic for UC, this paper suggests the specific first agent may influence long-term remission time.
Discussing relative effectiveness and treatment goals with a clinician when choosing a first biologic is reasonable.
Keep In Mind
This is an observational real-world study summarized in the journal abstract. Propensity-score adjustment was used, but observational studies can have residual confounding. The abstract does not replace a full-text review for treatment decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationIntestinal Research
PublisherKorean Association for the Study of Intestinal Diseases
AuthorsDiari M’Baye, Marianne Hupé, Marie Dodel +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 31, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Adherence to advanced therapies in inflammatory bowel diseases: Real-world rates and predictors of non-adherence.
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
This large real‑world comparison helps show how different advanced therapies performed over 1 year in routine practice, highlighting that ustekinumab had strong outcomes overall while upadacitinib was most effective in...